Candel Therapeutics, Inc. (CADL) announced overall survival data from a phase II study evaluating its lead investigational adenovirus immunotherapy candidate, CAN-2409 plus valacyclovir (prodrug), together with standard of care (SoC) in patients with stage III/IV non-small cell lung cancer (NSCLC) who are non-responsive to immune checkpoint inhibitor therapy.Data from the study showed that treatment with two administrations of CAN-2409 plus valacyclovir led to a median overall survival of 20.6 months in NSC ...